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Abstract
The aim of the present study was to determine whether estrogen
therapy (ET) reduces alterations of the autonomic control of heart rate
(HR) due to hypoestrogenism and aging. Thirteen young (24 ± 2.6
years), 10 postmenopausal (53 ± 4.6 years) undergoing ET (PM-ET),
and 14 postmenopausal (56 ± 2.6 years) women not undergoing ET
(PM) were studied. ET consisted of 0.625 mg/day conjugated equine
estrogen. HR was recorded continuously for 8 min at rest in the supine
and sitting positions. HR variability (HRV) was analyzed by time
(SDNN and rMSSD indices) and frequency domain methods. Power
spectral components are reported as normalized units (nu) at low (LF)
and high (HF) frequencies, and as LF/HF ratio. Intergroup compari-
sons: SDNN index was higher in young (median: supine, 47 ms;
sitting, 42 ms) than in PM-ET (33; 29 ms) and PM (31; 29 ms) women
(P < 0.05). PM showed lower HFnu, higher LFnu and higher LF/HF
ratio (supine: 44, 56, 1.29; sitting: 38, 62, 1.60) than the young group
in the supine position (61, 39, 0.63) and the PM-ET group in the sitting
position (57, 43, 0.75; P < 0.05). Intragroup comparisons: HR was
lower in the supine than in the sitting position for all groups (P < 0.05).
The HRV decrease from the supine to the sitting position was signifi-
cant only in the young group. These results suggest that HRV de-
creases during aging. ET seems to attenuate this process, promoting a
reduction in sympathetic activity on the heart and contributing to the
cardioprotective effect of estrogen hormones.
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Introduction
Epidemiological studies have demon-
strated that, after menopause, women pres-
ent an increased incidence of cardiovascular
disease (1). It is believed that this higher
vulnerability is related to the occurrence of
decreased estrogen levels during this period
(2). During the last decade, the positive ef-
fect of hormone therapy on the incidence of
coronary artery diseases (CAD) as well as on
the morbidity and mortality of cardiovascu-
lar disease has been demonstrated (3,4). The
mechanisms involved in the prophylactic
action of estrogens may be mainly related to
the promotion of an antiatherogenic lipid
profile and the action on blood vessel walls
(5,6). More recently, however, two large
scale randomized clinical studies on post-
menopausal women with (7) or without (8)
CAD indicated that hormone therapy may
not be beneficial and may actually increase
the risk of cardiovascular events (8).
The study of heart rate variability (HRV)
is an important tool for a noninvasive evalu-
ation of the integrity of neurocardiac func-
tion (9). It has been proposed that a decrease
in HRV is a powerful predictor of morbidity
and mortality consequent to arrhythmic com-
plications (10).
Autonomic modifications of cardiovas-
cular control have also been observed in the
aging process (11,12). In women, both aging
and postmenopausal hormonal changes con-
tribute to modifications of the autonomic
control of the heart. Brockbank et al. (13)
and Liu et al. (14) noted higher HRV values
in premenopausal than in postmenopausal
women. Mercuro et al. (15) observed de-
creased HRV indices in women submitted to
bilateral oophorectomy. However, when
these patients were placed on therapy with
17ß-estradiol, all HRV indices returned to
their pre-surgery levels. Others (14,16-18)
have investigated whether hormone therapy
could influence the action of the autonomic
nervous system on the heart. Yet, the prob-
lem remains without a definitive solution.
The objective of the present study was to test
the hypothesis that the use of estrogen thera-
py could attenuate changes in the autonomic
control of heart rate (HR) due to the hypoes-
trogenism that accompanies the aging pro-
cess since a decrease in HRV has been asso-
ciated with increased risks for cardiac events
(10).
Material and Methods
A cross-sectional study was conducted
on 37 healthy young and postmenopausal
women who fulfilled established criteria.
The young subjects presented regular men-
strual cycles and were not using anticoncep-
tional drugs. Experimental procedures were
always performed during the follicular phase
of their cycle, when hormonal variations are
not influenced by progesterone. The post-
menopausal state was defined as age above
48 years, the absence of a menstrual cycle
for the last 12 months for patients who had
uterus and serum follicular-stimulating hor-
mone levels above 30 mIU/mL. None of the
subjects followed any program of regular
aerobic exercise. Subjects showing evidence
of cardiac or respiratory disease, hyperten-
sion (blood pressure ≥140/90 mmHg), dia-
betes mellitus, thromboembolic disease,
dysthyroidism, stroke, depression, obesity
(body mass index ≥30 kg/m2), or a history of
smoking or alcoholism were excluded from
the study. None of the subjects were using
sedatives, anti-hypertensive or anti-arrhyth-
mic medication, or other medications able to
affect autonomic control of HR.
Thirteen young women, 14 postmeno-
pausal women not undergoing hormone
therapy and 10 women undergoing estrogen
therapy for at least one year took part in the
study. In the last group, all women had a
previous history of hysterectomy and were
continuously using oral conjugated equine
estrogen at doses of 0.625 mg/day. This
hormonal treatment had been indicated to
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subjects showing vasomotor symptoms, os-
teopenia or osteoporosis. Age and anthropo-
metric and clinical characteristics of the sub-
jects in the groups studied are presented in
Table 1.
Blood pressure was measured to confirm
that it was within normal limits. Two meas-
urements were performed on two non-con-
secutive days by the brachial artery auscul-
tatory method using a mercury column
sphygmomanometer (WanMed, São Paulo,
SP, Brazil) and a stethoscope (Littmann, St.
Paul, MN, USA). For this procedure the
subjects remained at rest in the sitting posi-
tion for at least 5 min, with feet on the floor,
and the arm supported at heart level (19).
The mean blood pressure values are reported
in Table 1.
All subjects included in the present study
had blood count, urinalysis and electrocar-
diogram at rest within normal limits. The
results of the maximum treadmill exercise
test were negative for myocardial ischemia
and arrhythmia in all cases. Additionally,
the results of clinical biochemical screening
tests (glucose, total cholesterol and frac-
tions, triglycerides, urea, creatinine, thyroid-
stimulating hormone, and serum estradiol)
are presented in Table 2.
The subjects were also submitted to a
continuous dynamic exercise test up to physi-
cal exhaustion on a cycle ergometer (model
Corival 400, Quinton, Seattle, WA, USA)
with 10 to 20 W/min increments. During the
test, ventilatory and metabolic measurements
were obtained on a breath-by-breath basis
using a specific metabolic analyzer (CPX-
D, Medical Graphics, St. Paul, MN, USA).
Aerobic capacity was then evaluated using
oxygen uptake ( ) data obtained at the
peak of exercise.
The study was approved by the Ethics
Committee of the University Hospital, Fac-
ulty of Medicine of Ribeirão Preto, Univer-
sity of São Paulo, and by the Ethics Commit-
tee of the Federal University of São Carlos,
São Carlos, SP, Brazil. The purpose of the
study was explained to each subject prior to
obtaining written informed consent.
Measurement of heart rate variability
Experiments were always carried out in
the morning in order to avoid response dif-
ferences due to circadian changes. Room
temperature was kept at 22ºC and relative air
humidity between 40 and 60%. Subjects
were acquainted with the experimental pro-
tocol and instructed to abstain from stimu-
lants and alcoholic beverages during the 24
h preceding the exam, and to ingest a light
meal at least 2 h prior to the measurement.
On each experimental day, the subjects
were interviewed and examined prior to the
beginning of the test to verify their contin-
ued good health and if they had had a normal
night’s sleep. After a 15-min rest in the
supine position, blood pressure and HR were
measured to determine whether the basal
conditions of the subjects were adequate for
the experiment.
An electrocardiogram and HR data were
obtained from a one-channel heart monitor
(TC500, ECAFIX, São Paulo, SP, Brazil)
and processed using an analog-to-digital con-
verter Lab. PC+ (National Instruments Co.,
Austin, TX, USA), which represented the
interface between the heart monitor and a
Pentium III microcomputer. Signals were
recorded in real time after analog-to-digital
conversion at a sampling rate of 500 Hz, and
the R-R intervals (ms) were calculated on a
beat-to-beat basis using specific software
(20). To evaluate the effect of body position
on the HR response and its variability, R-R
intervals were recorded over an 8-min pe-
riod under resting conditions with the sub-
jects in the supine and sitting positions, re-
spectively, and breathing spontaneously.
HRV was assessed in both time and fre-
quency domains. The region of greatest sta-
bility for the gathering of the R-R intervals
was used for this measurement, so that at
least 256 consecutive beats (9) were pre-
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sented. The selected time domain param-
eters studied were the mean of the R-R inter-
vals, the standard deviation of the R-R inter-
vals (SDNN) and the square root of the mean
of the sum of the squares of differences
between adjacent R-R intervals (rMSSD).
SDNN reflected overall HRV, whereas
rMSSD was considered to be an index of
parasympathetic modulations of HR (9).
For the frequency domain, spectral anal-
ysis was performed by fast Fourier transfor-
mation applied to a single window after a
linear trend subtraction, at the R-R intervals
previously chosen. The power spectral com-
ponents were obtained at low (LF: 0.04 to
0.15 Hz) and high (HF: 0.15 to 0.4 Hz)
frequencies, in absolute units (ms2), and the
normalized units were computed by divid-
ing the absolute power of a given LF or HF
component (ms2) by the total power minus
very low frequency (0.003-0.04 Hz) power
and then multiplying this ratio by 100. Since
the LF band is modulated by both the sym-
pathetic and the parasympathetic nervous
systems and the HF band is correlated with
vagal cardiac control, the LF/HF ratio was
calculated to determine the sympatho-vagal
balance (9). Figure 1, which was drawn us-
ing an autoregressive model, illustrates the
HRV power spectra at rest in the supine and
sitting positions of a representative subject
from each group.
Statistical analysis
One-way ANOVA was performed to
compare the physical and clinical character-
istics of the three experimental groups and,
when appropriate, post hoc analyses were
conducted using the Tukey HSD for unequal
N. HRV indices obtained during the experi-
mental trials were tested for normality. Since
the data were shown not to be normally
distributed, comparisons between groups
were performed using the Kruskal-Wallis
test and, when appropriate, post hoc analy-
ses were conducted using Dunn’s multiple
comparison test. For intragroup analysis, the
Wilcoxon matched-pair test was used. For
association between variables, the Spear-
man correlation test was used. The level of
significance was set at P < 0.05. Data are
reported as medians followed by 95% confi-
dence intervals. Figures 1 and 2 were drawn
using MatLab software 6.1.0.450, release
12.1.
Results
No significant differences in weight or
height were observed between groups. The
subjects of the younger group had lower
Figure 1. Heart rate variability power spectra of a representative subject from the groups of
young women (A and B), postmenopausal women undergoing (C and D) and not undergo-
ing (E and F) estrogen therapy obtained at rest in the supine and sitting positions, respec-
tively. Spectral components are shown as low frequency (0.04 to 0.15 Hz), high frequency
(0.15 to 0.4 Hz) and very low frequency (below 0.04 Hz).
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body mass index, blood pressure and a higher
peak, reported as absolute and normal-
ized values for body weight, than the post-
menopausal groups (P < 0.05; Table 1). No
significant differences in mean menopausal
time periods were observed between the post-
menopausal groups. The average period of
estrogen therapy used was 6 ± 4.6 years.
Table 2 shows that there were no signifi-
cant differences in serum concentrations of
glucose, triglyceride, HDL cholesterol, urea,
creatinine, or thyroid-stimulating hormone
between groups. The young group presented
significantly lower (P < 0.05) total choles-
terol values compared to the postmenopausal
groups, and lower LDL cholesterol values
compared to subjects not using estrogen.
Serum follicular-stimulating hormone lev-
els did not differ between the postmeno-
pausal groups, but the serum estradiol levels
were higher in the postmenopausal group
undergoing estrogen therapy (P < 0.05).
Intergroup comparisons showed that HR
and R-R intervals at rest did not differ be-
tween the groups studied. However, analysis
of the time domain demonstrated that the
group of young subjects presented signifi-
cantly (P < 0.05) higher values for the SDNN
index compared to those of the two post-
menopausal groups. The rMSSD index of
the younger group was higher than those of
the postmenopausal groups, but the differ-
ence was only statistically significant (P <
0.05) in relation to the subjects not using
estrogens (Table 3). Frequency domain anal-
ysis showed that the postmenopausal group
not undergoing hormone therapy presented
lower values of the HF normalized unit
(HFnu) components (P < 0.05), and higher
LFnu components and LF/HF ratio (P <
0.05) relative to the young group, in the
supine position (Table 3), and the postmeno-
pausal group undergoing estrogen therapy,
in the sitting position (Table 3 and Figure 2).
No significant correlation was observed
between HRV and body mass index, 
peak, triglycerides, or total cholesterol and
Table 1. Age and anthropometric and clinical characteristics of the groups studied.
Characteristics Young PM with ET PM without ET
(N = 13) (N = 10) (N = 14)
Age (years) 24 ± 2.6 53 ± 4.6* 56 ± 2.6*
Weight (kg) 57 ± 6.0 66 ± 9.9 62 ± 9.4
Height (cm) 163 ± 6.0 157 ± 5.8 158 ± 6.1
BMI (kg/m2) 21.6 ± 2.5 26.6 ± 4.0* 24.8 ± 3.2*
SBP (mmHg) 99 ± 8.6 114 ± 11.7* 118 ± 17.6*
DBP (mmHg) 67 ± 5.5 76 ± 6.9* 76 ± 10.4*
V
.
O2peak (mL/min) 1287 ± 148.5 918 ± 114.3* 929 ± 150.6*
V
.
O2peak (mL kg-1 min-1) 22.6 ± 3.1 14.2 ± 1.5* 14.8 ± 2.7*
Menopause time (years) - 7 ± 4.6 8 ± 4.8
ET time (years) - 6 ± 4.6 -
Data are reported as means ± SD. PM = postmenopausal; ET = estrogen therapy; BMI
= body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure;
V
.
O2 = oxygen uptake.
*P < 0.05 compared to young women (one-way ANOVA and post hoc Tukey test).
Table 2. Clinical biochemical characteristics of the groups studied.
Young PM with ET PM without ET
(N = 13) (N = 10) (N = 14)
Glucose (mg/dL) 80 ± 6.2 86 ± 9.2 88 ± 11.2
Triglyceride (mg/dL) 78 ± 28.9 141 ± 70.1 133 ± 69.5
Total cholesterol (mg/100 mL) 174 ± 28.5 221 ± 51.0* 216 ± 38.2*
LDL cholesterol (mg/100 mL) 102 ± 28.3 134 ± 39.7 140 ± 35.6*
HDL cholesterol (mg/100 mL) 56 ± 9.7 59 ± 10.4 49 ± 14.8
Urea (mg/dL) 32 ± 3.6 28 ± 4.6 28 ± 6.9
Creatinine (mg/dL) 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.2
TSH (mIU/mL) 2.0 ± 0.7 1.6 ± 1.5 2.5 ± 2.0
FSH (mIU/mL) - 60 ± 38.2 75 ± 45.2
Serum estradiol (pg/mL) - 58 ± 25.4 23 ± 5.4**
Data are reported as means ± SD. PM = postmenopausal; ET = estrogen therapy; LDL
= low-density lipoprotein; HDL = high-density lipoprotein; TSH = thyroid-stimulating
hormone; FSH = follicular-stimulating hormone.
*P < 0.05 compared to young women; **P < 0.05 compared to PM women with ET
(one-way ANOVA and post hoc Tukey test).
fractions. However, LFnu, HFnu and LF/HF
ratio (sitting position) presented a signifi-
cant correlation with serum estradiol levels
(rs = -0.59, 0.59, and -0.59, respectively; P <
0.05).
In intragroup comparisons, lower HR
values and higher values for the R-R inter-
vals in the supine position were observed in
relation to the sitting position in all three
groups studied. These differences were sta-
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while others failed to find any modifications
(16,18). Christ et al. (24) observed a de-
creased HRV and considered this effect to
be restricted to a subgroup that used estro-
gen plus progesterone.
The objective of the present investiga-
tion was to evaluate the relative influence of
age, hypoestrogenism and estrogen therapy
on the autonomic control of HR during rest
in the supine and sitting positions.
Autonomic modulation of HR has been
documented as progressively declining with
aging. This process has been demonstrated
both by the reduction of vagal activity indi-
ces and of indices that reflect sympathetic
activity on the heart (11,25). Since signifi-
cantly decreased temporal indices of HRV
were observed in postmenopausal women
our results agree with the literature. Although
the present study shows decreased aerobic
capacity, increased body mass index and
lipid profile modifications with aging, these
variables did not present a significant corre-
lation with HRV indices. Similar results were
observed by Byrne et al. (26), suggesting
that age is the major factor responsible for
HRV reduction in the aging.
However, hypoestrogenism is another
factor that could have influenced our results
because the estrogen-treated group presented
intermediate HRV values. Previous studies
have also shown changes in the autonomic
control of HR following natural (12-14,27)
or surgical menopause (15). In agreement
with the results of these studies, our results
show that menopause can cause an imbal-
ance of the autonomic nervous control of the
cardiovascular system that shifts toward sym-
pathetic hyperactivity. This could explain,
in part, the increased incidence of cardiovas-
cular diseases observed in postmenopausal
women (1).
We also observed that postmenopausal
women using estrogen therapy presented
higher HFnu values and lower LFnu values,
as well as lower LF/HF ratio compared to
non-users of hormones. Considering our ex-
Table 3. Heart rate variability at rest in the supine and sitting positions.
Variable Young PM with ET PM without ET
(N = 13) (N = 10) (N = 14)
Supine position
Heart rate (bpm) 70 (65;75) 66 (61;72) 66 (64;68)
R-R interval (ms) 860 (804;916) 904 (831;979) 912 (878;947)
SDNN (ms) 47 (40;54) 33 (27;39)* 31 (27;36)*
rMSSD (ms) 43 (32;54) 28 (20;35) 19 (16;22)*
LF (nu) 39 (32;46) 41 (32;50) 56 (51;61)*
HF (nu) 61 (54;68) 59 (50;68) 44 (39;49)*
LF/HF 0.63 (0.42;0.84) 0.70 (0.41;1.00) 1.29 (1.04;1.54)*
Sitting position
Heart rate (bpm) 74 (68;80)*** 72 (65;79)*** 69 (65;72)***
R-R interval (ms) 808 (748;868)*** 832 (749;915)*** 872 (823;921)***
SDNN (ms) 42 (32;52) 29 (26;32)* 29 (26;33)*
rMSSD (ms) 37 (31;43)*** 24 (19;29) 17 (14;20)*
LF (nu) 49 (40;58)*** 43 (35;50) 62 (58;66)**
HF (nu) 51 (42;60)*** 57 (50;65) 38 (34;42)**
LF/HF 0.96 (0.57;1.35)*** 0.75 (0.50;0.99) 1.60 (1.29;1.91)**
Data are reported as medians and 95% confidence intervals. PM = postmenopausal;
ET = estrogen therapy; SDNN = standard deviation of the R-R intervals; rMSSD =
square root of the mean of the sum of the squares of differences between adjacent R-
R intervals; LF = low frequency; HF = high frequency; nu = normalized units; LF/HF =
low frequency/high frequency ratio.
*P < 0.05 compared to young women; **P < 0.05 compared to PM women with ET; ***P
< 0.05 compared to the supine position (intergroup comparisons: Kruskal-Wallis and
post hoc Dunn test; intragroup comparisons: Wilcoxon test).
tistically significant (P < 0.05; Table 3).
Concerning HRV, only the group of young
subjects presented decreased (P < 0.05) indi-
ces, reflecting vagal activity (rMSSD and
HFnu) and an increase (P < 0.05) in the
indices reflecting sympathetic activity (LFnu
and the LF/HF ratio) in the sitting position
compared to the supine position. Figure 1
shows the differences in the distribution of
spectral components for both body positions
for a representative subject from each group.
Particularly in the young group, a predomi-
nance of the HF and LF components was
observed in the supine and sitting position,
respectively.
Discussion
The effects of hormone therapy on HRV
indices have been reported in heterogeneous
and controversial forms, with some studies
presenting favorable results (14,17,21-23),
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perimental design, some factors could have
influenced these results, such as age, anthro-
pometric characteristics, clinical status, bio-
chemical tests, and aerobic capacity. How-
ever, no significant differences were ob-
served between the postmenopausal groups
for any of the variables measured, except for
the serum estradiol levels and the HRV indi-
ces described above, which showed a statis-
tically significant correlation. These find-
ings suggest that there is a significant rela-
tionship between several HRV indices and
serum estradiol levels (estrogen therapy) in
the postmenopausal women studied.
Therefore, the present findings agree with
previous studies (14,15,27), which have re-
ported increased vagal activity and reduced
sympathetic drive in postmenopausal women
undergoing estrogen therapy. Nevertheless,
the mechanism responsible for the benefi-
cial effect of estrogen therapy on autonomic
control of HR remains unknown and should
be explored in future studies.
The divergence in the literature on the
effects of hormone therapy on HRV may be
due to the different types of hormones used,
as well as to differences in dosage and route
of administration. The patient’s age at hor-
mone utilization and prescription also ap-
pears to interfere with the results. Indeed, at
this time, the results of the Heart and Estro-
gen/Progestin Replacement Study (7) and of
the Women’s Health Initiative (WHI) Study
(8) regarding the increased risk of cardio-
vascular events have been questioned be-
cause the mean age of the patients was very
high. Actually, the WHI data showed sig-
nificant differences in the risk of CAD be-
tween groups corrected by age, and the re-
sults showed a lower risk of CAD in estro-
gen-treated patients at the age of 60 years or
less (28). Therefore, hormonal therapy must
begin at the appropriate time (“window of
opportunity”) when endothelial function is
still normal. In the present study, the meno-
pause period of the estrogen-treated group
was still within the time span when hormone
Figure 2. Low frequency normalized units (nu) (A), high frequency (nu) (B) and low
frequency/high frequency (LF/HF) ratio (C) in young and postmenopausal (PM) women with
or without estrogen therapy (ET), measured at rest in the sitting position. *P < 0.05 for the
comparisons (Kruskal-Wallis and post hoc Dunn test).
therapy has favorable effects on the cardio-
vascular system.
The postural change from the supine to
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the sitting position provokes a reduction in
venous return and a consequent HR eleva-
tion due to cardiac autonomic regulation
(i.e., sympathetic activation and decreased
vagal activity), which are mediated by arte-
rial and cardiopulmonary baroreceptor ad-
justment (29). In the present study, all groups
presented modifications in the chronotropic
response as a function of body position. On
the other hand, variation of sympatho-vagal
modulation was only noted in the younger
group. These results suggest that the barore-
flex control of HR could be altered by the
aging process since increased vascular in-
tima media thickness, associated with lumi-
nal dilatation and a reduction in compliance,
could be responsible for the decline in car-
diovascular baroreflex sensitivity in older
subjects (30,31). Previous studies in young
(32) and middle-aged subjects (32,33) have
demonstrated alterations in HRV indices due
to postural changes. Other investigators have
reported that these changes lose their statis-
tical significance with advancing age (34,35).
The cross-sectional design of this study
is a limitation, since the characteristics of the
autonomic control of HR in postmenopausal
women prior to the use of estrogen therapy
were not known. However, rigorous criteria
of inclusion and exclusion in the study were
established in order to control the factors
that could influence autonomic control of
the heart.
The results of the present study suggest
that age plays an important role in auto-
nomic cardiac modulation in female sub-
jects. Estrogen therapy, in turn, seems to
attenuate age-related modifications of the
autonomic control of HR by promoting re-
duced sympathetic hyperactivity of the heart,
thus contributing to the cardioprotector ef-
fect described in earlier studies (3,4). Fur-
thermore, our results indicate that physi-
ological levels of estrogens are responsible
for a higher vagal and lower sympathetic
modulation of HR in our subjects. Studies
are underway in our laboratory to evaluate
the effects of long-term physical activity and
hormonal therapy on the cardiovascular re-
sponse at rest and during the exercise.
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